Baidu
map

Stroke:三甲胺氮氧化物与卒中复发的关系取决于缺血性卒中亚型

2021-11-21 MedSci原创 MedSci原创

TMAO水平升高与小动脉闭塞亚型患者卒中复发风险增加相关,但这种关联似乎在大动脉粥样硬化、心源性栓塞和其他亚型中有所减弱。

三甲胺N-氧化物(TMAO)已被公认为是血管疾病的危险因素。然而,TMAO在缺血性卒中中的作用尚未明确。众所周知,缺血性脑卒中是一种发病机制多样的异质性疾病。近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员旨在根据病因亚型研究TMAO与卒中复发之间的关联。

该研究共纳入了第三届中国卒中登记中心的10756例缺血性卒中/短暂性脑缺血发作患者,研究人员分析了卒中复发的1年随访资料。TOAST(急性中风治疗中的ORG10172试验)标准用于对病因亚型进行分类。受试者血浆TMAO水平是通过液相色谱-质谱法进行定量。研究人员使用Cox回归模型分析了TMAO与卒中结局之间的关联,研究人员还对TMAO水平与卒中风险的关联进行了荟萃分析。

在多变量Cox回归模型中,TMAO水平升高与卒中复发风险独立相关(Q4与Q1:调整后的风险比为1.37[95%CI为1.15-1.64])。

按T​​OAST亚型分层后,TMAO与小动脉闭塞亚型的卒中复发之间存在显著关联(调整风险比为1.43[95%CI为1.03-2.00]),但在其他亚型(大动脉粥样硬化为1.19[0.95-1.48];心源性栓塞为1.54[0.95-2.48];其他为1.19[0.98-1.44])。荟萃分析报告了最高与最低TMAO水平的卒中复发汇总风险比为1.66(95%CI为0.91-3.01),同样发现卒中复发风险增加。

由此可见,TMAO水平升高与小动脉闭塞亚型患者卒中复发风险增加相关,但这种关联似乎在大动脉粥样硬化、心源性栓塞和其他亚型中有所减弱。

原始出处:

Jie Xu.et al.Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes.stroke.2021.https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.031443

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1968777, encodeId=7bb91968e7749, content=<a href='/topic/show?id=2b323600566' target=_blank style='color:#2F92EE;'>#卒中亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36005, encryptionId=2b323600566, topicName=卒中亚型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Tue Jan 04 09:20:59 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806477, encodeId=fe0418064e74c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 09 16:20:59 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893448, encodeId=2882189344834, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 19 16:20:59 CST 2022, time=2022-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391633, encodeId=9f35139163387, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552547, encodeId=29ce155254e55, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1968777, encodeId=7bb91968e7749, content=<a href='/topic/show?id=2b323600566' target=_blank style='color:#2F92EE;'>#卒中亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36005, encryptionId=2b323600566, topicName=卒中亚型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Tue Jan 04 09:20:59 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806477, encodeId=fe0418064e74c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 09 16:20:59 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893448, encodeId=2882189344834, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 19 16:20:59 CST 2022, time=2022-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391633, encodeId=9f35139163387, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552547, encodeId=29ce155254e55, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1968777, encodeId=7bb91968e7749, content=<a href='/topic/show?id=2b323600566' target=_blank style='color:#2F92EE;'>#卒中亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36005, encryptionId=2b323600566, topicName=卒中亚型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Tue Jan 04 09:20:59 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806477, encodeId=fe0418064e74c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 09 16:20:59 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893448, encodeId=2882189344834, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 19 16:20:59 CST 2022, time=2022-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391633, encodeId=9f35139163387, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552547, encodeId=29ce155254e55, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1968777, encodeId=7bb91968e7749, content=<a href='/topic/show?id=2b323600566' target=_blank style='color:#2F92EE;'>#卒中亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36005, encryptionId=2b323600566, topicName=卒中亚型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Tue Jan 04 09:20:59 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806477, encodeId=fe0418064e74c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 09 16:20:59 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893448, encodeId=2882189344834, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 19 16:20:59 CST 2022, time=2022-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391633, encodeId=9f35139163387, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552547, encodeId=29ce155254e55, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1968777, encodeId=7bb91968e7749, content=<a href='/topic/show?id=2b323600566' target=_blank style='color:#2F92EE;'>#卒中亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36005, encryptionId=2b323600566, topicName=卒中亚型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Tue Jan 04 09:20:59 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806477, encodeId=fe0418064e74c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Oct 09 16:20:59 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893448, encodeId=2882189344834, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 19 16:20:59 CST 2022, time=2022-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391633, encodeId=9f35139163387, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552547, encodeId=29ce155254e55, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Tue Nov 23 03:20:59 CST 2021, time=2021-11-23, status=1, ipAttribution=)]

相关资讯

Stroke:颅内闭塞的轻度缺血性卒中患者的影像学特征

三分之一的轻度卒中患者会发生早期神经功能恶化,主要是由于相关颅内闭塞。近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员分析了这些患者的血管闭塞模式、血栓特征和再通率。

Radiology:遇到急性缺血性卒中患者时,一定要看看有没有这些征象!

在急性缺血性卒中的患者中,阻塞的血管导致供血区域脑组织的氧气供应不足。

Stroke:COVID-19住院患者缺血性卒中的风险、临床过程和结局

COVID-19住院患者急性缺血性卒中的累积发生率约为2%,在重症监护病房接受治疗的患者风险更高。大多数卒中患者的预后不佳。缺血性卒中与肺栓塞之间的关联值得进一步研究。

Stroke:低血压、合并症与缺血性卒中死亡率的关系

与正常血压相比,卒中前较低的血压与卒中后死亡率相关,尤其是在至少有一种合并症的患者中。

Stroke : 卒中患者,出院后,他们康复如何?

该研究的重要意义提供了一套基于专家共识的关键因素,在确定脑卒中患者出院后护理的地点时需要考虑

Neurology:优化急性缺血性卒中的血管内血栓摘除术的早期血压管理可改善患者预后

血管内血栓摘除术后24小时内平均收缩压水平升高与症状性颅内出血、早期神经恶化、3个月死亡率和3个月功能预后较差的几率增加独立相关。

Baidu
map
Baidu
map
Baidu
map